



Published in final edited form as:

Bioorg Med Chem Lett. 2007 March 1; 17(5): 1266–1269.

A novel diketo phosphonic acid that exhibits specific, strand-transfer inhibition of HIV integrase and anti-HIV activity

Guochen Chi^a, Vasu Nair^{a,*}, Elena Semenova^b, and Yves Pommier^b

^aThe Center for Drug Discovery and the Department of Pharmaceutical and Biomedical Sciences, University of Georgia, Athens, GA 30602, USA

^bLaboratory of Molecular Pharmacology, National Cancer Institute, NIH, Bethesda, MD 20892, USA

Abstract

We have synthesized novel phosphonic acid analogues of β -diketo acids. Interestingly, the phosphonic acid isostere, **2**, of our anti-HIV compound, **1**, was an inhibitor of only the strand transfer step, in stark contrast to **1**. Compound **2** had lower anti-HIV activity than **1**, but was more active and less toxic than the phosphonic acid analogue of L-708906. These isosteric compounds represent the first examples of β -diketo phosphonic acids of structural, synthetic and antiviral interest.

Keywords

Synthesis; Phosphonates; HIV integrase inhibitors; Mechanism of inhibition; Anti-HIV activity

The *pol* gene of the human immunodeficiency virus (HIV) encodes viral enzymes that are required for HIV replication.^{1–3} Drug design and discovery work directed at inhibitors of two of these enzymes, HIV reverse transcriptase (RT) and HIV protease (PR), have created clinically-useful compounds for the treatment of acquired immunodeficiency syndrome (AIDS).^{4–8} However, research efforts on drug discovery pertaining to the third enzyme of the *pol* gene, HIV integrase, have not produced a single approved drug whose mechanism of action is inhibition of HIV integrase.^{9–11} As HIV integrase has no human counterpart and is important in HIV replication, it remains a key viral target for the design and discovery of new anti-HIV agents.

HIV-1 integrase is encoded at the 3'-end of the HIV *pol* gene and is a relatively small (32 kDa) viral protein. Its catalysis results in the incorporation of HIV DNA into host chromosomal DNA.^{12–16} This process begins in the cytoplasm where the viral DNA, produced by reverse transcription, is assembled on HIV integrase. Following this assembly, there is specific endonucleolytic cleavage of two nucleotides from each 3'-end of double-stranded viral DNA. This step, referred to as 3'-processing, produces tailored and recessed viral DNA. The next step, which occurs in the nucleus, is identified as strand transfer. Following staggered nicking of chromosomal DNA and joining of each 3'-end of the recessed viral DNA to the 5'-ends of the host DNA, there is repair, which completes the integration process. The strand transfer step, occurring in the nucleus, is partitioned from the 3'-processing step in the cytoplasm.

*Corresponding author. Tel.: +1 706-542-6293; fax: +1 706-583-8283; e-mail: vnair@rx.uga.edu.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

While many structurally diverse compounds have been reported to be inhibitors of HIV integrase,^{8–10,17–28} only a few compounds of one group, the β -diketo acids, and their related compounds, represent the most convincing, biologically-validated inhibitors^{23,24} of this viral enzyme. Nair and coworkers have designed a conceptually new β -diketo acid with a nucleobase scaffold, compound **1**, which is a powerful inhibitor of both 3'-processing and strand transfer steps of HIV-1 integrase and which exhibits remarkably potent *in vitro* anti-HIV activity.^{29, 30}

Phosphonic acids have been viewed commonly as mimics of carboxylic acids, particularly with reference to biological activity. For example, amino phosphonic acids, isosteres of amino acids, reveal diverse biological properties.³¹ With this concept in mind, we designed the β -diketo phosphonic acids, **2** and **3**, the phosphorus-based isosteres of compounds **1** and **L-708906**. In this report, we describe the methodology for the syntheses of **2** and **3** and discuss their integrase inhibition and antiviral data.

Although the β -diketo acid **1** was synthesized, using as the key step, the condensation of acetyl uracil **4** with dimethyl oxalate under basic conditions,²⁹ the related reaction of **4** with trimethyl phosphonoformate was unsuccessful (Scheme 1). The reason for this may be the instability of the C(O)-P(O) bond of trimethyl phosphonoformate under basic conditions.³² Therefore, an alternative synthetic route was devised (Scheme 2).

Thus, 5-formyl uracil **7** was benzylated to give **8** (89%). Compound **8** was condensed with ethyl diazoacetate in the presence of tin (II) chloride³³ to afford **9**, which was transformed into its protected form **10** (28% yield from **8**). Reduction of **10** to the corresponding aldehyde with diisobutylaluminum hydride at -78°C , followed by a Pudovik reaction with dimethyl phosphite and triethylamine, proceeded to form the phosphonate **11** (50% for two steps). The ketal group of **11** was deprotected to produce the key intermediate **12**, which was purified by HPLC (65% yield) and fully characterized by multinuclear NMR and HRMS data.³⁴ Dess-Martin oxidation of **12** produced diketone **6**, which exists largely in the enolic form. Compound **6** was deprotected by stirring with NaI in acetone for 3 days.³⁵ The resulting precipitate was collected and washed with acetone to afford the sodium methyl phosphonate **13** (67% yield). However, compound **13** could not be further deprotected with NaI, even under acetone reflux conditions, possibly because of the presence of the negative charge on the phosphonyl group and the poor solubility of **13** in acetone.³⁵ The problem was circumvented by conversion of **13** to its protonated form by ion-exchange chromatography with Dowex 50 \times 8 in methanol to afford **14**. When compound **14** was heated under reflux with 5 equivalents of NaI in acetone for 24 h and the resulting crystalline precipitate was collected and washed with acetone, the target phosphonate **2** (monosodium salt) was produced in a highly purified form (51% yield). Compound **3** was synthesized by a similar procedure to compound **2**. The structures of **2** and **3** were confirmed by ^1H , ^{13}C and ^{31}P NMR and HRMS data.³⁴

Integrase inhibition studies were conducted with recombinant wild-type HIV-1 integrase and a 21-mer oligonucleotide substrate following a previously described procedure.^{36,37} Target compound **2** was not an inhibitor of the 3'-processing step of HIV integrase ($\text{IC}_{50} > 333 \mu\text{M}$) but inhibited the strand transfer step ($\text{IC}_{50} 20.2 \pm 7.2 \mu\text{M}$).³⁸ The integrase inhibition activity of **2** is in sharp contrast to that of compound **1**, which is a potent inhibitor of both the 3'-processing and strand transfer steps of integrase ($\text{IC}_{50} 3.7 \pm 1.0 \mu\text{M}$ and $0.2 \pm 0.1 \mu\text{M}$, respectively^{29,39} and $14.4 \pm 1.6 \mu\text{M}$ and $4.5 \pm 2.5 \mu\text{M}$, respectively³⁸).

Compound **2** was tested in a PBMC cell-based, microtiter anti-HIV assay against the clinical isolate, HIV-1_{TEKI} (NSI phenotype) and HIV-1_{NL4-3} (SI phenotype).²⁹ Antiviral determinations were performed in triplicate with serial $\frac{1}{2}\log_{10}$ dilution of the test materials (six to nine concentrations total). The overall performance of both assays was validated by the

MOI-sensitive positive control compound, AZT. As summarized in Table 1, *in vitro* anti-HIV studies against HIV-1 isolates in PBMC showed that compound **2** (highest test concentration = 200 μ M) was active with IC₅₀ values in the low μ M range and with antiviral efficacy data [therapeutic indices, TI = CC₅₀/IC₅₀ of >50 (HIV-1_{TEKI}) and >62 (HIV-1_{NL4-3})]. Cell viability data showed only mild cellular cytotoxicity at the highest test concentrations; however, a CC₅₀ (>200 μ M) was not reached. In contrast, compound **3** was significantly less active and more toxic [TI = 5.8 (HIV-1_{TEKI}) and 4.0 (HIV-1_{NL4-3})]. The control compound, AZT (highest test concentration = 1 μ M), gave therapeutic indices of >504 (HIV-1_{TEKI}) and >573 (HIV-1_{NL4-3}).

In summary, we have developed a methodology for the synthesis of a new β -diketo phosphonic acid, **2**, an isostere of our highly-active, anti-HIV compound, **1**. In complete contrast to **1**, compound **2** specifically inhibits only the strand transfer step of WT HIV-1 integrase. Anti-HIV data show that the exchange of the carboxylate functionality with a phosphonate results in a reduction in *in vitro* anti-HIV activity. The anti-HIV data in PBMC may be a reflection of the difference in integrase inhibitory activity of **1** compared to **2** and the result of decreased cellular permeability of phosphonate **2** compared to the less polar carboxylate **1**. Interestingly, compound **2** is more anti-HIV active and less toxic than the phosphonic acid analogue of **L-708906** (compound **3**). Finally, these isosteric compounds represent the first examples of β -diketo phosphonic acids of structural, synthetic and antiviral interest.

Acknowledgements

This project was supported by Grant No. RO1 AI 43181 from the National Institutes of Health (NIAID) and by the Intramural Research Program of the NIH, National Cancer Institute, Center for Cancer Research. The contents of this paper are solely the responsibility of the authors and do not necessarily represent the official views of the NIH. We thank the SRI for the anti-HIV screening data.

References and notes

1. Fauci AS. Science 1988;239:617. [PubMed: 3277274]
2. Katz RA, Skalka AM. Annu Rev Biochem 1994;63:133. [PubMed: 7526778]
3. Frankel AD, Young JAT. Annu Rev Biochem 1998;67:1. [PubMed: 9759480]
4. De Clercq E. Nature Rev Drug Discovery 2002;1:13.
5. De Clercq E. Clin Microbiol Rev 1997;10:674. [PubMed: 9336668]
6. Johnson, SC.; Gerber, JG. Advances in Internal Medicine. Schrier, RW.; Baxter, JD.; Dzau, VJ.; Fauci, AS., editors. 45. Mosby; St. Louis: 2000. p. 1-40.
7. Nair V, St Clair MH, Reardon JE, Krasny HC, Hazen RJ, Paff MT, Boone LR, Tisdale M, Najera I, Dornsife RE, Averett DR, Borroto-Esoda K, Yale JL, Zimmerman TP, Rideout JL. Antimicrob Agents Chemother 1995;39:1993. [PubMed: 8540705]
8. De Clercq E. J MedChem 2005;48:1297.
9. Pommier Y, Johnson AA, Marchand C. Nature Rev Drug Discovery 2005;4:236.
10. Nair V. Frontiers in Med Chem 2005;2:3.
11. Dayam R, Neamati N. Curr Pharm Design 2003;9:1789.
12. Asante-Appiah E, Skalka AM. Adv Virus Res 1999;52:351. [PubMed: 10384242]
13. Esposito D, Craigie R. Adv Virus Res 1999;52:319. [PubMed: 10384240]
14. Dyda F, Hickman AB, Jenkins TM, Engelman A, Craigie R, Davies DR. Science 1994;266:1981. [PubMed: 7801124]
15. Wu Y, Marsh JW. Science 2001;293:1503. [PubMed: 11520990]
16. Espeseth AS, Felock P, Wolfe A, Witmer M, Grobler J, Anthony N, Egbertson M, Melamed JY, Young S, Hamill T, Cole JL, Hazuda DJ. Proc Natl Acad Sci USA 2000;97:11244. [PubMed: 11016953]
17. Mazumder A, Uchida H, Neamati N, Sunder S, Jaworska-Maslanka M, Wickstrom E, Zeng F, Jones RA, Mandes RF, Chenault HK, Pommier Y. Mol Pharmacol 1997;51:567. [PubMed: 9106620]

18. Taktakishvili M, Neamati N, Pommier Y, Pal S, Nair V. *J Am Chem Soc* 2000;122:5671.
19. Hazuda DJ, Felock P, Witmer M, Wolfe A, Stillmock K, Grobler JA, Espeseth A, Gabryelski L, Schleif W, Blau C, Miller MD. *Science* 2000;287:646. [PubMed: 10649997]
20. Wai JS, Egbertson MS, Payne LS, Fisher TE, Embrey MW, Tran LO, Melamed JY, Langford HM, Guare JP Jr, Zhuang L, Grey VE, Vacca JP, Holloway MK, Naylor-Olsen AM, Hazuda DJ, Felock PJ, Wolfe AL, Stillmock KA, Schleif WA, Gabryelski LJ, Young SD. *J Med Chem* 2000;43:4923. [PubMed: 11150161]
21. Marchand C, Zhang X, Pais GCG, Cowansage K, Neamati N, Burke TR Jr, Pommier Y. *J Biol Chem* 2002;277:12596. [PubMed: 11805103]
22. Hazuda DJ, Young SD, Guare JP, Anthony NJ, Gomez RP, Wai JS, Vacca JP, Handt L, Motzel SL, Klein HJ, Dornadula G, Danovich RM, Witmer MV, Wilson KAA, Tussey L, Schleif WA, Gabryelski LS, Jin L, Miller MD, Casimiro DR, Emini EA, Shiver JW. *Science* 2004;305:528. [PubMed: 15247437]
23. Grobler JA, Stillmock K, Hu B, Witmer M, Felock P, Espeseth AS, Wolfe A, Egbertson M, Bourgeois M, Melamed J, Wai JS, Young S, Vacca J, Hazuda DJ. *Proc Natl Acad Sci USA* 2002;99:6661. [PubMed: 11997448]
24. Goldgur Y, Craigie R, Cohen GH, Fujiwara T, Yoshinaga T, Fujishita T, Sugimoto H, Endo T, Murai H, Davies DR. *Proc Natl Acad Sci USA* 1999;96:13040. [PubMed: 10557269]
25. Yoshinaga, T.; Sato, A.; Fujishita, T.; Fujiwara, T. 9th Conference on Retroviruses and Opportunistic Infections; Seattle, WA. February 24–28, 2002; Abstract 8, p 55
26. Pannecouque C, Pluymers W, Van Maele B, Tetz V, Cherepanov P, De Clercq E, Witvrouw M, Debyser Z. *Curr Biol* 2002;12:1169. [PubMed: 12176326]
27. Pais GCG, Zhang X, Marchand C, Neamati N, Cowansage K, Svarovskaia ES, Pathak VK, Tang Y, Nicklaus M, Pommier Y, Burke TR Jr. *J Med Chem* 2002;45:3184. [PubMed: 12109903]
28. Sato M, Motomura T, Aramaki H, Matsuda T, Yamashita M, Ito Y, Kawakami H, Matsuzaki Y, Watanabe W, Yamataka K, Ikeda S, Kodama E, Matsuoka M, Shinkai H. *J Med Chem* 2006;49:1506. [PubMed: 16509568]
29. Nair V, Chi G, Ptak R, Neamati N. *J Med Chem* 2006;49:445. [PubMed: 16420027]
30. Nair V, Uchil V, Neamati N. *Bioorg Med Chem Lett* 2006;16:1920. [PubMed: 16439124]
31. Kukhar, VP.; Hudson, HR., editors. *Aminophosphonic and Aminophosphinic Acids, Chemistry and Biological Activity*. John Wiley and Sons, Ltd; Chichester: 2000.
32. Sekine M, Kume A, Nakajima M, Hata T. *Chem Lett* 1981:1087.
33. Holmquist CR, Roskamp EJ. *J Org Chem* 1989;54:3258.
34. Data for dimethyl 3-(1,3-dibenzyl-2,4-dioxo-1,2,3,4-tetra-hydropyrimidin-5-yl)-1-hydroxy-3-oxopropylphosphonate (**12**). ¹HNMR (CDCl₃): 8.29 (s, 1H), 7.30–7.50 (m, 10H), 5.18 (s, 2H), 5.05 (d, 1H, J=15), 5.02 (d, 1H, J=15), 4.61 (m, 1H), 3.87 (d, 3H, J=11.0), 3.86 (d, 3H, J=10.5), 3.57–3.64 (m, 1H), 3.42–3.48 (m, 1H). ¹³CNMR (CDCl₃): 194.9 (d, J=17.6), 160.8, 150.9, 149.3, (136.2, 134.3, 129.5, 129.2, 129.1, 128.7, 128.5, 128.1, phenyl ring), 111.7 (d, J=2.31), 64.3 (d, J=169.4), 53.8, (53.72, 53.68, 53.66, 53.61, P-OCH₃), 45.1, 43.9 (d, J=3.82). ³¹PNMR (CDCl₃): 26.5. FAB-HRMS: calcd for C₂₃H₂₆N₂O₇P (M+H)⁺ 473.1478, found 473.1469. Data for 3-(1,3-dibenzyl-2,4-dioxo-1,2,3,4-tetrahydro-pyrimidin-5-yl)-1-hydroxy-3-oxoprop-1-enylphosphonic acid (**2**) as its monosodium salt: mp 224°C(dec.). ¹HNMR (CD₃OD): 8.58 (s, 1H), 7.22–7.39 (m, 11H), 5.12 (s, 2H), 5.10 (s, 2H). ¹³CNMR (CD₃OD): 188.1 (d, J=14.5), 185.9 (d, J=190.4), 161.5, 152.5, 150.6, (138.3, 137.1, 130.2, 129.6, 129.5, 129.3, 128.7, phenyl ring), 111.2 (d, J=4.90), 104.5 (d, J=24.4), 54.4, 45.7. ³¹PNMR (CD₃OD): 0.82. FAB-HRMS: calcd for C₂₁H₁₉N₂NaO₇P (M+H)⁺ 465.0828, found 465.0840. Data for 3-(3,5-bis(benzyloxy)phenyl)-1-hydroxy-3-oxoprop-1-enyl-phosphonic acid (**3**) as its monosodium salt: mp 201°C(dec.). ¹HNMR (CD₃OD): 7.29-7.46 (m, 10H), 7.25 (d, 2H, J=2.5), 6.89 (d, 1H, J=7.0), 6.85 (t, 1H, J=2.5), 5.12 (s, 4H). ¹³CNMR (CD₃OD): 193.3 (d, J=13.4), 185.0 (d, J=191.3), [161.8, 140.0 (d, J=4.27), 138.4, 129.7, 129.2, 128.9, 108.3, 107.8, phenyl ring], 101.6(weak), 71.5. ³¹PNMR (CD₃OD): 0.91. FAB-HRMS: calcd for C₂₃H₂₁NaO₇P (M+H)⁺ 463.0923, found 463.0927.
35. Karaman R, Goldblum A, Breuer E, Leader H. *J Chem Soc, Perkin Trans 1* 1989:765.
36. Mazumder, A.; Neamati, N.; Sundar, S.; Owen, J.; Pommier, Y. *Antiviral Methods and Protocols*. Kinchington, D.; Schinazi, R., editors. 24. Humana; Totowa: 1999. p. 327-338.

37. Marchand C, Johnson AA, Karki RG, Pai GC, Zhang X, Cowansage K, Burke TR, Pommier Y. *Mol Pharmacol* 2003;64:600. [PubMed: 12920196]
38. Magnesium chloride-based assay.
39. Manganese chloride-based assay.






Figure 1. Structures of two biologically-active diketo acids (top) and their phosphonic acid isosteres (bottom).

**Scheme 1.**

The difference in the reactivity of **4** with dimethyl oxalate compared to trimethyl phosphonoformate.

**Scheme 2.**

Synthesis of integrase inhibitor **2**.

Reagents and conditions: a) BnBr/DMF/K₂CO₃; b) N₂CHCO₂Et/SnCl₂/CH₂Cl₂; c) Ethylene glycol/CH(OEt)₃/PTS; d) Dibal-H/toluene /-78°C; e) HP(O)(OMe)₂/Et₃N/MeOH; f) PTS/acetone/H₂O; g) Dess-Martin periodinane/CH₂Cl₂; h) NaI/acetone; i) Dowex50Wx8-100/MeOH; j) NaI/acetone/reflux.

Table 1

Antiviral data for compounds of Figure 1 in PBMC

Comps	HIV-1 Isolate Cell Line	IC ₅₀	CC ₅₀	TI
1 [#]	HIV-1 _{TEKI} (PBMC)	50 nM	>200 μM	>4,000
	HIV-1 _{NL4-3} (PBMC)	<20 nM	>200 μM	>10,000
L708906 [†]	HIV-1 (IIB) (MT-4)	5.5 μM	88.3 μM	16
2	HIV-1 _{TEKI} (PBMC)	4.0 μM	>200 μM	>50
	HIV-1 _{NL4-3} (PBMC)	3.2 μM	>200 μM	>62
3	HIV-1 _{TEKI} (PBMC)	8.1 μM	46.9 μM	5.8
	HIV-1 _{NL4-3} (PBMC)	11.8 μM	46.9 μM	4.0

[#] Ref 29,[†] Ref 26